Evidence map›Paper›PMID 35976464›Full record

ArticleAnnals of surgical oncology2022

Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.

Fulvio Borella, Stefano Cosma, Domenico Ferraioli, Isabelle Ray-Coquard, Nicolas Chopin, Pierre Meeus, Vincent Cockenpot, Giorgio Valabrega, Giulia Scotto, Margherita Turinetto and 12 more

Erratum issuedAbstract readMulticenter Study
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Fulvio BorellaDivision of Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy. fulvio.borella@unito.it.
Stefano CosmaDivision of Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy.
Domenico FerraioliLéon Bérard Comprehensive Cancer Center, Lyon, France.
Isabelle Ray-CoquardLéon Bérard Comprehensive Cancer Center, Lyon, France.
Nicolas ChopinLéon Bérard Comprehensive Cancer Center, Lyon, France.
Pierre MeeusLéon Bérard Comprehensive Cancer Center, Lyon, France.
Vincent CockenpotLéon Bérard Comprehensive Cancer Center, Lyon, France.
Giorgio ValabregaDepartment of Oncology, University of Turin, Turin, Italy.
Giulia ScottoDepartment of Oncology, University of Turin, Turin, Italy.
Margherita TurinettoDepartment of Oncology, University of Turin, Turin, Italy.
Nicoletta BigliaDivision of Obstetrics and Gynecology - A.O. Ordine Mauriziano, University of Turin, Turin, Italy.
Luca FusoDivision of Obstetrics and Gynecology - A.O. Ordine Mauriziano, University of Turin, Turin, Italy.
Luca MarianiDivision of Obstetrics and Gynecology - A.O. Ordine Mauriziano, University of Turin, Turin, Italy.
Dorella FranchiPreventive Gynecology Unit, European Institute of Oncology IRCCS, Milan, Italy.
Ailyn Mariela Vidal UrbinatiPreventive Gynecology Unit, European Institute of Oncology IRCCS, Milan, Italy.
Ida PinoPreventive Gynecology Unit, European Institute of Oncology IRCCS, Milan, Italy.
Gianluca BertschyDivision of Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy.
Mario PretiDivision of Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy.
Chiara BenedettoDivision of Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy.
Isabella CastellanoPathology Unit, Department of Medical Sciences, University and City of Health and Science, Turin, Italy.
Paola CassoniPathology Unit, Department of Medical Sciences, University and City of Health and Science, Turin, Italy.
Luca BerteroPathology Unit, Department of Medical Sciences, University and City of Health and Science, Turin, Italy.

Funding

The present study was supported by grants from Rete Oncologica del Piemonte e Valle d'Aosta and Fondazione Cassa di Risparmio di Torino file number: 2021.0553).
6 · The paper itself

Abstract

backgroundThe term uterine smooth muscle tumor of uncertain malignant potential (STUMP) indicates a rare, equivocal entity between benign leiomyomas and leiomyosarcomas. In the present study, we evaluated a comprehensive range of clinical, surgical, and pathological features in a large multicenter series of patients with STUMP to identify risk factors for recurrence.

methodsThis is a retrospective study performed by collecting consecutive cases diagnosed between January 2000 and December 2020 in five tertiary centers. Associations between STUMP recurrence and clinicopathological characteristics as well as surgical treatment modality were investigated.

resultsEighty-seven patients affected by STUMP were considered. Of them, 18 cases (20.7%) recurred: 11 as leiomyosarcoma (LMS) and 7 as STUMP. The mean time to recurrence was 79 months. We found that fragmentation/morcellation, epithelioid features, high mitotic count, Ki-67 value > 20%, progesterone receptor (PR) < 83%, and p16 diffuse expression were associated with higher risk of recurrence and shorter recurrence-free survival (RFS). Furthermore, morcellation/fragmentation and mitotic count remained independent risk factors for recurrence and shorter RFS after multivariate analysis, while the presence of epithelioid features was an independent risk factor for recurrence only.

conclusionsOur results suggest that morcellation is associated with risk of recurrence and shorter RFS, thus it should be avoided if a STUMP is suspected preoperatively. Epithelioid features, high proliferation activity, low PR expression, and diffuse p16 expression are also unfavorable prognostic factors, so patients presenting these features should be closely followed up.

Indexed as

LeiomyomaLeiomyosarcomaSmooth Muscle TumorUterine NeoplasmsFemaleHumansImmunohistochemistryRetrospective Studies

Identifiers

PMID35976464
PMCPMC9640445

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.